Validity of the SF-12 quality of life instrument in patients with retinal diseases
Validity of the SF-12 quality of life instrument in patients with retinal diseases
复制标题
DOI：
10.1016/s0161-6420(02)01124-7
复制
发表时间：
2002-10-01
期刊：
影响因子：
13.7
通讯作者：
Azen, S
中科院分区：
文献类型：
--
作者：
Globe, DR;Levin, S;Azen, S
目的：探讨SF-12与SF-36综合得分在视网膜疾病患者中的结构效度和信度。设计：横断面研究。研究对象：1,081名在某第三转诊大学视网膜诊所就诊的视网膜疾病患者。方法：每个患者在首次眼科检查前完成SF-36。SF-12是根据SF-36的12个条目组成的子集。主要结果：SF-36和SF-12确定的身体综合得分和心理综合得分。结果：839(78%)的受试者在SF-12上身体综合得分和心理综合得分可评。总体而言，SF-36和SF-12在PCS和MCS方面没有发现显著差异，并按四个最常见的疾病类别分层(均为P>；0.20)。在疾病类别间，SF-36和SF-12的平均得分(P<；0.001)和SF-36的MCS得分差异有统计学意义(P=0.04)。SF-12的PCS和MCS得分与SF-36的相似指标(综合分和分量表)高度相关。结论：SF-12是眼科研究中反映一般健康状况的有效工具，只要不同眼病组之间的心理综合得分不同即可。减少给药时间的好处使SF-12成为推荐的一般生活质量结果工具。(C)2002年，由美国眼科学会提供。
Objective: To investigate the construct validity and reliability of the SF-12 with the SF-36 composite scores in patients with retinal diseases.Design: Cross-sectional study.Participants: One thousand eighty-one patients with retinal disease presenting for care at a tertiary referral university-based retina practice.Methods: Each patient completed the SF-36 before his or her initial ocular examination. The SF-12 is based on a subset of 12 items from the SF-36.Main Outcome Measures: Physical Composite Score (PCS) and Mental Composite Score (MCS) as determined by the SF-36 and SF-12.Results: Eight hundred thirty-nine (78%) of the participants had scorable PCS and MCS scores on the SF-12. No significant differences were found between the SF-36 and SF-12 for the PCS and MCS overall and stratified by the four most frequently occurring disease categories (all P > 0.20). There were statistically significant differences across the disease categories in the mean PCS scores (P < 0.001) on the SF-36 and SF-12 and the MCS score on the SF-36 (P = 0.04). The SF-12 PCS and MCS scores were highly correlated with similar indicators (composite scores and subscales) on the SF-36.Conclusions: The SF-12 is a valid measure of general health status for ophthalmic research, as long as differences in mental composite scores do not need to be demonstrated between different ocular disease groups. The benefit of reduced administration time makes the SF-12 a recommended general quality-of-life outcomes tool. (C) 2002 by the American Academy of Ophthalmology.